Therapy de-escalation in pediatric patients with inflammatory bowel disease in remission: Data analysis from the CEDATA registry
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Stepping down combination therapy in pediatric inflammatory bowel disease (IBD) is often successful in Crohn's disease (CD) patients. De-escalating to a single TNF-alpha-inhibitor therapy is more advantageous than other approaches.
Area Of Science
- Pediatric gastroenterology
- Immunomodulatory therapy
- Inflammatory bowel disease (IBD) management
Background
- Standardized criteria for stepping down combination therapy (immunomodulator and TNF-alpha-inhibitors) in pediatric IBD are lacking.
- De-escalation aims to reduce side effect risks while maintaining disease control.
Purpose Of The Study
- To describe de-escalation practices in a large pediatric IBD cohort.
- To identify prognostic factors for successful de-escalation without requiring further therapy adjustments.
Main Methods
- Analysis of real-world data from the CEDATA-GPGE registry (2004-2023).
- Comparison of patients who did and did not require therapy adjustments post-de-escalation.
- Identification of prognostic factors for successful de-escalation.
Main Results
- Crohn's disease (CD) patients were more frequently on combination therapy and more successfully de-escalated than ulcerative colitis (UC) or IBD-unclassified patients.
- Successful de-escalation was more likely in UC patients with less severe disease.
- De-escalation to biologic monotherapy was more successful than to immunomodulator monotherapy or cessation of both agents.
Conclusions
- De-escalation of combination therapy is more likely to be successful in pediatric CD patients.
- De-escalating to TNF-alpha-inhibitor monotherapy is a more advantageous strategy.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...